ORENCIA DIN 02461919
Health Canada record
| Active ingredient(s) | ABATACEPT 125 MG |
|---|---|
| Dosage form | Solution |
| Route | Subcutaneous |
| Schedule | SCHEDULE D; PRESCRIPTION |
| Class | Human |
| ATC | L04AA24 ABATACEPT |
| Original market date | |
| Current status date | 15-Aug-2022 |
| Source | Health Canada DPD |
Establishment licence of the holder
Bristol-Myers Squibb Canada — licence 100100, currently licensed, last inspection rating C (2026-03-18).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ABATACEPT
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02282097 | ORENCIA | BRISTOL-MYERS SQUIBB CANADA | Powder For Solution | ABATACEPT 250 MG | Marketed |
| 02402475 | ORENCIA | BRISTOL-MYERS SQUIBB CANADA | Solution | ABATACEPT 125 MG | Marketed |